Morgan Stanley Downgrades Salesforce (NYSE:CRM) to Equalweight From Overweight, Sees Near-Term Catalysts ‘in Rear-View Mirror’, Lifts Price Target to $278 From $251.
Morgan Stanley Downgrades Salesforce (NYSE:CRM) to Equalweight From Overweight, Sees Near-Term Catalysts ‘in Rear-View Mirror’, Lifts Price Target to $278 From $251.